Management outcome and follow-up of fetal tachycardia

Division of Pediatric Cardiology, University of Utrecht, The Netherlands.

OBJECTIVES. The aim of this study was to evaluate fetal tachycardia and the efficacy of maternally administered antiarrhythmic agents and the effect of this therapy on delivery and postpartum management. BACKGROUND. Sustained fetal tachycardia is a potentially life-threatening condition in which pharmacologic therapy is reported to be effective. There is ongoing discussion about optimal management. METHODS. A group of 51 patients with M-mode echocardiographically documented fetal tachycardia was studied retrospectively. RESULTS. Thirty-three fetuses had supraventricular tachycardia; 15 had atrial flutter; 1 had two episodes of both; and 2 had ventricular tachycardia. Fetal hydrops was seen in 22 patients. Thirty-four fetuses received maternal therapy with either digoxin or flecainide as the first administered drug (additional drugs were given in 12). Drug treatment was successful in establishing acceptable rhythm control in 82% (84% without, 80% with hydrops). In the latter group the median number of drugs and number of days to conversion were higher. Three patients with fetal hydrops died. In 50% of cases, tachycardia reappeared at delivery: 9 neonates presented with atrial flutter, 14 with supraventricular tachycardia and 1 with ventricular tachycardia. Seventy-eight percent of the group had pharmacologic therapy by 1 month of age and 14% by 3 years. CONCLUSIONS. Fetal tachycardia can be treated adequately in the majority of patients, even in the presence of hydrops, and therefore emergency delivery might not be indicated. Digoxin and flecainide were drugs of first choice and produced no serious adverse effects in this series of patients. The majority of patients do not require prolonged therapy.

This article has been cited by other articles:

				L. K Hornberger and D. J Sahn Rhythm abnormalities of the fetus Heart, October 1, 2007; 93(10): 1294 - 1300. [Full Text] [PDF]

				D S Kothari and J R Skinner Neonatal tachycardias: an update. Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2006; 91(2): F136 - F144. [Abstract] [Full Text] [PDF]

				H. R. Singh, S. Garekar, M. L. Epstein, and T. L'Ecuyer Neonatal Supraventricular Tachycardia (SVT) NeoReviews, July 1, 2005; 6(7): e339 - e350. [Full Text] [PDF]

				J. F. Strasburger, B. F. Cuneo, M. M. Michon, N. L. Gotteiner, B. J. Deal, S. N. McGregor, M. A. Oudijk, E. J. Meijboom, L. Feinkind, M. Hussey, et al. Amiodarone Therapy for Drug-Refractory Fetal Tachycardia Circulation, January 27, 2004; 109(3): 375 - 379. [Abstract] [Full Text] [PDF]

				M. A. Oudijk, J. M. Ruskamp, F. F. T. Ververs, E. B. Ambachtsheer, P. Stoutenbeek, G. H. A. Visser, and E. J. Meijboom Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics J. Am. Coll. Cardiol., August 20, 2003; 42(4): 765 - 770. [Abstract] [Full Text] [PDF]

				M Krapp, T Kohl, J M Simpson, G K Sharland, A Katalinic, and U Gembruch Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia Heart, August 1, 2003; 89(8): 913 - 917. [Abstract] [Full Text] [PDF]

				A.J.J.T. Rein, C. O'Donnell, T. Geva, A. Nir, Z. Perles, I. Hashimoto, X.-K. Li, and D.J. Sahn Use of Tissue Velocity Imaging in the Diagnosis of Fetal Cardiac Arrhythmias Circulation, October 1, 2002; 106(14): 1827 - 1833. [Abstract] [Full Text] [PDF]

				H.L. Tan and K.I. Lie Treatment of tachyarrhythmias during pregnancy and lactation Eur. Heart J., March 2, 2001; 22(6): 458 - 464. [PDF]

				M. A. Oudijk, M. M. Michon, C. S. Kleinman, L. Kapusta, P. Stoutenbeek, G. H. A. Visser, and E. J. Meijboom Sotalol in the Treatment of Fetal Dysrhythmias Circulation, June 13, 2000; 101(23): 2721 - 2726. [Abstract] [Full Text] [PDF]

				L. A. Lisowski, P. M. Verheijen, A. A. Benatar, D. J. G. Soyeur, P. Stoutenbeek, J. I. Brenner, C. S. Kleinman, and E. J. Meijboom Atrial flutter in the perinatal age group: diagnosis, management and outcome J. Am. Coll. Cardiol., March 1, 2000; 35(3): 771 - 777. [Abstract] [Full Text] [PDF]

				T. Kohl, P. F. Kirchhof, W. Gogarten, J. Reckers, B. Asfour, R. Witteler, W. Haverkamp, L. Eckardt, A. E. Marcus, H. VanAken, et al. Fetoscopic Transesophageal Electrocardiography and Stimulation in Fetal Sheep : A Minimally Invasive Approach Aimed at Diagnosis and Termination of Therapy-Refractory Supraventricular Tachycardias in Human Fetuses Circulation, August 17, 1999; 100(7): 772 - 776. [Abstract] [Full Text] [PDF]

				C. WREN Mechanisms of fetal tachycardia Heart, June 1, 1998; 79(6): 536 - 537. [Full Text]

				J M Simpson and G K Sharland Fetal tachycardias: management and outcome of 127 consecutive cases Heart, June 1, 1998; 79(6): 576 - 581. [Abstract] [Full Text]

				E Jaeggi, J C Fouron, A Fournier, N van Doesburg, S P Drblik, and F Proulx Ventriculo-atrial time interval measured on M mode echocardiography: a determining element in diagnosis, treatment, and prognosis of fetal supraventricular tachycardia Heart, June 1, 1998; 79(6): 582 - 587. [Abstract] [Full Text]

				R. Bajoria, N. M. Fisk, and S. F. Contractor Liposomal Thyroxine: A Noninvasive Model for Transplacental Fetal Therapy J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3271 - 3277. [Abstract] [Full Text] [PDF]